# Addiction Medicine Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Billie Holiday (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML010-SYN-TD
- Date: 1948-04-27
- Fictional facility: St. Posthumous Health Center
- Fictional author: Julian Ortiz, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Constance Mayfield, MD

## Reason for consultation

Severe opioid use disorder and moderate alcohol use disorder in a 33-year-old singer, five weeks after release from about ten months in custody, when her tolerance is low and her overdose risk high. Buprenorphine with naloxone was started today. Please confirm the medication plan and dose, advise on a medicine for her drinking that is safe with buprenorphine, and help set the monitoring and recovery plan. **S**

## History

Ms. Holiday, a 33-year-old singer, is seen at the request of Dr. Mayfield one week after starting buprenorphine with naloxone. She has taken every dose, 4 mg on the first day and 8 mg since, and has used no opioids. She has had no withdrawal, but cravings return each evening, especially after shows. She drinks four or five drinks on performance nights to calm her nerves. She has no history of withdrawal seizures or delirium. She sought treatment for heroin use years ago and says she wants to stay off it and keep singing. Her biggest fear is overdosing now that her tolerance is low. She tours often and worries about getting prescriptions filled on the road. She asked that this note be shared only with Dr. Mayfield. **S**

## Examination

| System | Finding |
|---|---|
| General | Alert and engaged; blood pressure 122/78, pulse 78 |
| Eyes | Pupils normal in size; no tearing |
| Skin | No injection-site changes or abscesses |
| Neurological | No tremor |
| Psychiatric | Calm and direct; no signs of intoxication or withdrawal |

BP 122/78 mmHg; pulse 78 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 98% on room air; weight 68.2 kg; BMI 25.1 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Mayfield's intake note with the safety assessment, AUDIT-C, DAST-10, and PHQ-9. Last week's results: AST 52, ALT 38, GGT 84 U/L; albumin 4.0 g/dL; bilirubin 0.7 mg/dL; MCV 101 fL; platelets 236; creatinine 0.72 mg/dL; PEth 312 ng/mL; hepatitis C antibody nonreactive (0.09); hepatitis B surface antigen and core antibody nonreactive, surface antibody 3 mIU/mL; HIV antigen-antibody nonreactive. Today's urine drug test: buprenorphine and norbuprenorphine only. Prescription drug monitoring program: no other controlled-substance prescriptions. 

## Assessment

1. **Opioid use disorder, severe, early in buprenorphine treatment** (F11.20). Buprenorphine is a good choice: it lowers the risk of overdose death, can be prescribed from primary care, and fits her touring better than daily methadone clinic attendance, which remains an option if buprenorphine does not control her cravings. Extended-release naltrexone would need a long opioid-free period and does not protect her if she loses tolerance and uses again. Starting at a low dose was right after enforced abstinence. Evening cravings at 8 mg mean the dose is too low; most people do best at 16 mg or more. **S**
2. **Alcohol use disorder, moderate** (F10.20). Naltrexone, the usual first choice, cannot be used with buprenorphine. Acamprosate is safe with buprenorphine and with her normal kidney function; topiramate is a second choice. Her withdrawal risk is low, so she does not need a medically managed withdrawal. **S**
3. **Liver**. AST higher than ALT with a raised GGT and a high MCV points to alcohol. Albumin, bilirubin, and platelets are normal, and FIB-4 is 1.18, below 1.3, so advanced fibrosis is unlikely and elastography is not needed now. Repeating liver tests as drinking changes, and FIB-4 within a year, is enough. She is not immune to hepatitis B and should complete the series. **S**
4. **Return to use**. A return to use is common and is a reason to strengthen treatment, not to stop it. Her greatest risk is a gap in her medication while touring. **S**

## Recommendations

1. Increase buprenorphine with naloxone to 16 mg once daily today.
2. Start acamprosate 666 mg three times daily; continue thiamine while she drinks heavily.
3. Naloxone at home and in her bag, with her friend trained; fentanyl test strips; never use alone.
4. Visits every one to two weeks for the first month, then every two to four weeks until stable, then monthly; telehealth check-ins when she is on tour.
5. Urine drug testing with fentanyl at most visits early on, explained as part of care, never as a condition of treatment; check the prescription drug monitoring program before each prescription.
6. PEth with liver tests at each check while she is drinking; FIB-4 again at six to twelve months; elastography only if FIB-4 reaches 1.3.
7. Complete the hepatitis A and B vaccine series; repeat hepatitis C and HIV testing yearly while any drug use continues.
8. If she returns to use, keep her on buprenorphine, increase support, and look for the cause; consider monthly extended-release buprenorphine if gaps in supply recur.
9. Plan for tours before each trip: a pharmacy chain that can fill in any state, prior authorization kept current, an early fill, and a travel letter.
10. Offer counseling and peer recovery support without making them a condition of medication.

## Strengths and supports

- Supports: musicians she has worked with for years, a close friend who has agreed to carry naloxone, and a peer recovery coach; her music is her strongest source of purpose **S**

## Communication

Discussed with Dr. Mayfield, who sees her the same day. The plan was explained to Ms. Holiday, who agreed with it; at her request this note is shared only with Dr. Mayfield and is held under the federal confidentiality rule for substance use disorder records. **S**

## Follow-up

Addiction medicine review at three months or sooner if there is a return to use; Dr. Mayfield continues prescribing. **S**

## Guideline basis

- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Treatment Options for Substance Use Disorder (medications for opioid and alcohol use disorders) (2026), Substance Abuse and Mental Health Services Administration
- VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (2021), United States Department of Veterans Affairs and Department of Defense
- Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases (2019), American Association for the Study of Liver Diseases (Hepatology)
- AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis (2025), American Association for the Study of Liver Diseases (Hepatology)
- Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations — United States, 2023 (2023), Centers for Disease Control and Prevention (MMWR Recommendations and Reports)
